• In late January 2026, Intel reported a quarterly and full‑year loss, filed an omnibus shelf registration for debt and equity securities, and issued guidance for a loss-making first quarter of 2026.
• At the same time, speculation about Apple potentially using Intel’s foundry, insider share purchases by Intel’s CFO, and a new AI memory collaboration with SoftBank’s Saimemory highlighted renewed external interest in Intel’s manufacturing and AI infrastructure ambitions.
• We’ll now examine how the potential Apple foundry partnership, alongside these developments, reshapes Intel’s investment narrative for investors.

AI is about to change healthcare. These 108 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Intel's Investment Narrative?

For Intel to make sense in a portfolio right now, you have to believe that its heavy manufacturing build‑out, foundry push and AI bets can eventually justify years of volatile results and thin returns. The latest quarter’s loss, soft Q1 2026 guidance and the new omnibus shelf registration underline how capital intensive that path is, while also reminding investors that further debt or equity issuance is on the table. Against that, rumors of Apple considering Intel’s foundry, progress on 18A and 14A, and the Saimemory AI‑memory tie‑up all speak to growing interest in Intel as a US manufacturing and AI infrastructure partner. In the near term, the real swing factors are whether Intel can convert this interest into firm high‑volume foundry wins and do so without eroding existing shareholders through dilution.

However, investors should also weigh how fresh capital raising could affect their stake over time. Intel's shares are on the way up, but could they be overextended? Uncover how much higher they are than fair value.

Exploring Other Perspectives

Twenty‑nine Simply Wall St Community fair value estimates span roughly US$28 to US$59, showing how far apart opinions sit on Intel’s worth. Set that against today’s renewed loss guidance, funding needs and foundry execution risks, and it becomes clear why you may want to review several of these perspectives before reaching your own conclusion.

Explore 29 other fair value estimates on Intel - why the stock might be worth as much as 19% more than the current price!

Build Your Own Intel Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Intel research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Intel research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intel's overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find companies with promising cash flow potential yet trading below their fair value.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.